Inactivation of YAP/TAZ by approved agents and their application as anti-breast cancer stem cell drugs
| Project/Area Number |
26830113
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Iwate Medical University |
|---|
Principal Investigator |
Oku Yusuke 岩手医科大学, 薬学部, 助教 (50626843)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | Hippo経路 / YAP/TAZ / スタチン / ダサチニブ / パゾパニブ / がん遺伝子 / 細胞内シグナル伝達 |
|---|
| Outline of Final Research Achievements |
We identified fluvastatin, dasatinib, pazopanib as agents inhibiting the function of oncogenic transcriptional co-activator, YAP/TAZ. They activate Hippo pathway and inhibit their nuclear localization. The sensitivity to these drugs of breast and colon cancer cell lines were correlated with the dependence on YAP/TAZ. Combination of these drugs efficiently reduced viability of MDA-MB-231 breast cancer cell lines. Furthermore, combination of these drugs with classical anti-cancer drugs synergistically reduced the viability of MDA-MB-231. These results suggest that these agents are effective for breast cancer cells with YAP/TAZ activation.
|
Report
(3 results)
Research Products
(15 results)
